[ad_1]
A pharmaceutical company is expanding its recall for blood pressure medications because of impurities that can cause cancer. This is part of a series of ongoing recalls that began in July 2018.
Torrent Pharmaceuticals Limited announced Thursday that it would recall another 36 batches of Losartan potbadium tablets USP and another 68 tablets of Losartan potbadium / hydrochlorothiazide due to the detection of traces of N-methylnitrosobutyric acid ( NMBA). lots in which the NMBA was above the acceptable daily intake levels published by the FDA.
You can see the relevant lots on this link.
The recall is the fourth extension of a first Torrent published in December 2018.
RELATED: Cancer Alert for Hypertension Treatment: 43 Other Batches Recalled
RELATED: Recall of new blood pressure medications due to cancer risk; now 5 in two weeks
It is advisable for patients using the recalled medication to continue taking it until they can talk to their doctor about alternatives. Stopping the use could also pose health risks.
Torrent said to have received no reports of adverse events related to the use of this medication.
The FDA has stated that impurities could occur when specific chemicals and reaction conditions are present in the API's manufacturing process of the drug (active pharmaceutical ingredients). This can also result from the reuse of materials, such as solvents. The FDA has generally stated that the risk of cancer is low.
[ad_2]
Source link
